Chemotactic signaling pathways in prostate cancer: Implications in the tumor microenvironment and as potential...

Area of Science:

• Oncology
• Immunology
• Cancer Biology

Background:

• Prostate cancer (PCa) is a leading cause of cancer death in men globally.
• Metastatic castration-resistant PCa (mCRPC) remains an incurable and challenging clinical problem.
• Current treatments for mCRPC have limited impact on overall survival.

Purpose of the Study:

• To explore tumor formation and PCa progression to mCRPC.
• To address challenges in enhancing anti-tumor immune responses in mCRPC.
• To examine targeting chemotactic signaling pathways as adjuvant therapies for mCRPC.

Main Methods:

• Review of tumor formation and PCa progression mechanisms.
• Analysis of chemotactic signaling's role in the tumor microenvironment, immune evasion, and cancer progression.
• Examination of pre-clinical and clinical studies on targeting chemokines and chemokine receptors.

Main Results:

• Chemotactic signaling significantly influences the tumor microenvironment, promoting immune evasion and cancer progression.
• Targeting specific chemokines and chemokine receptors shows potential as adjuvant therapies.
• Combination therapies involving mainstream treatments and targeted pathways may improve outcomes.

Conclusions:

• Understanding PCa progression to mCRPC is crucial for developing effective treatments.
• Targeting chemotactic signaling pathways offers a promising strategy to overcome immune evasion in mCRPC.
• Combination therapies hold the potential to maximize long-term survival for patients with advanced prostate cancer.